Safety and Immunogenicity of an AS03(B)-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study

Dengue disease and its causative agents, the dengue viruses (DENV-1–4), cause high morbidity in tropical and subtropical regions. We evaluated three dosing regimens of the investigational tetravalent AS03(B)-adjuvanted dengue-purified inactivated vaccine (DPIV+AS03(B)). In this phase 1/2, observer-b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Trop Med Hyg
Main Authors: Lin, Leyi, Lyke, Kirsten E., Koren, Michael, Jarman, Richard G., Eckels, Kenneth H., Lepine, Edith, McArthur, Monica A., Currier, Jeffrey R., Friberg, Heather, Moris, Philippe, Keiser, Paul B., De La Barrera, Rafael, Vaughn, David W., Paris, Robert M., Thomas, Stephen J., Schmidt, Alexander C.
Formato: Artigo
Idioma:Inglês
Publicado em: The American Society of Tropical Medicine and Hygiene 2020
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7356407/
https://ncbi.nlm.nih.gov/pubmed/32342848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4269/ajtmh.19-0738
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados